SMV5: Dr. Michael Triplett, CEO of Myonexus Therapeutics on its sale to Sarepta
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
SMV5: Dr. Michael Triplett, CEO of Myonexus Therapeutics on its sale to Sarepta
-
Narrado por:
-
De:
This episode of the SmartMoney Ventures Podcast features Dr. Michael Triplett, CEO of Myonexus Therapeutics who, along with co-founder Dr. Louise Rodino-Klapac, successfully completed a 9 figure exit event before securing Series A financing.
The story illustrates how successful tech transfer and strategic positioning resulted in the establishment of a new Gene Therapy Center of Excellence creating over 100 new jobs while transforming Muscular Dystrophy patient treatments.
Prior to co-founding Myonexus, Michael held leadership positions at Proctor & Gamble, Battelle Memorial Institute and Ventaira Pharmaceuticals among others.
In this episode, you will learn:
- How to get a 9 figure exit before your Series A financing
- How Technology Transfer is transforming the Heartland Region
- Why resilience is a big part of entrepreneurial psychology
- Sage advice for technical & scientific founders
- How a Gene Therapy Center of Excellence was established in Central Ohio
Dr. Triplett holds both a bachelor’s degree and a Ph.D. in Chemical Engineering from THE Ohio State University graduating Summa Cum Laude.